BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures.

Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors also participated, the Israel-based company said.

The funds will be used to advance the firm’s therapeutic pipeline towards clinical stages.

READ FULL ARTICLE HERE